Month: October 2022

HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;...

iSpecimen Launches New Open Feasibilities Dashboard on the iSpecimen Marketplace Platform to Enhance Biospecimen Fulfillment for Global Partner Network

New Feature Provides Suppliers with Research Transparency to Optimize Fulfillment ProcessLEXINGTON, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc....

error: Content is protected !!